Dementia - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 219 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dementia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dementia - Pipeline Review, H1 2016', provides an overview of the Dementia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia
- The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects
- The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dementia

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Dementia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dementia Overview 9
Therapeutics Development 10
Pipeline Products for Dementia - Overview 10
Pipeline Products for Dementia - Comparative Analysis 11
Dementia - Therapeutics under Development by Companies 12
Dementia - Therapeutics under Investigation by Universities/Institutes 15
Dementia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Dementia - Products under Development by Companies 20
Dementia - Products under Investigation by Universities/Institutes 24
Dementia - Companies Involved in Therapeutics Development 25
Adamas Pharmaceuticals, Inc. 25
AgeneBio Inc. 26
Alector LLC 27
AlzProtect SAS 28
Amarantus Bioscience Holdings, Inc. 29
Axon Neuroscience SE 30
Axovant Sciences Ltd. 31
BioArctic Neuroscience AB 32
Biogen, Inc. 33
Biotie Therapies Corp. 34
Boehringer Ingelheim GmbH 35
Chase Pharmaceuticals Corporation 36
Daewoong Pharmaceutical Co., Ltd. 37
Eisai Co., Ltd. 38
FORUM Pharmaceuticals Inc. 39
H. Lundbeck A/S 40
Heptares Therapeutics Limited 41
Hyundai Pharmaceutical Co., Ltd. 42
Ildong Pharmaceutical Co., Ltd. 43
Immungenetics AG 44
ImStar Therapeutics Inc. 45
Integrative Research Laboratories Sweden AB 46
Intellect Neurosciences, Inc. 47
Intra-Cellular Therapies, Inc. 48
MediPost Co., Ltd. 49
Neuraltus Pharmaceuticals, Inc. 50
Neurimmune Holding AG 51
Neurodyn Inc. 52
Oryzon Genomics S.A. 53
Ovid Therapeutics Inc. 54
P2D Bioscience 55
Pacific Northwest Biotechnology, LLC 56
Pivot Pharmaceuticals Inc 57
Sinil Pharmaceutical Co., Ltd 58
Stelic Institute & Co., Inc. 59
Sumitomo Dainippon Pharma Co., Ltd. 60
Sylentis S.A.U. 61
TauRx Therapeutics Ltd. 62
WhanIn Pharmaceutical Co., Ltd. 63
Dementia - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 69
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 76
AADvac-1 - Drug Profile 77
Antisense Oligonucleotides to Inhibit microRNA for Neurology - Drug Profile 78
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 79
AVCRI-104P3 - Drug Profile 80
AZP-2006 - Drug Profile 81
BAN-0805 - Drug Profile 83
BI-409306 - Drug Profile 84
CB-2233 - Drug Profile 86
CB-8411 - Drug Profile 87
choline alfoscerate SR - Drug Profile 88
CPC-201 - Drug Profile 89
CPC-252 - Drug Profile 90
D-217 - Drug Profile 91
dehydroevodiamine hydrochloride - Drug Profile 92
Drugs for Dementia - Drug Profile 93
Drugs to Agonize c-MET for Dementia - Drug Profile 94
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 95
DWJ-1365 - Drug Profile 96
E-2609 - Drug Profile 97
eltoprazine - Drug Profile 98
encenicline hydrochloride - Drug Profile 101
FRM-0334 - Drug Profile 104
GIBH-130 - Drug Profile 106
Gln-1062 - Drug Profile 107
GTC-6000 - Drug Profile 109
gugulipid - Drug Profile 110
HOB-075 - Drug Profile 111
HTL-18318 - Drug Profile 112
IRL-752 - Drug Profile 113
ITI-007 - Drug Profile 114
KR-12 - Drug Profile 116
levetiracetam - Drug Profile 117
LH-026 - Drug Profile 118
LUAF-20513 - Drug Profile 119
MM-201 - Drug Profile 120
Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile 121
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 122
NAT - Drug Profile 123
nelotanserin - Drug Profile 124
Neurostem - Drug Profile 125
NI-205 - Drug Profile 127
NI-308 - Drug Profile 128
NNC-269100 - Drug Profile 129
NP-001 - Drug Profile 130
OG-635 - Drug Profile 131
ORY-2001 - Drug Profile 132
OV-201 - Drug Profile 134
P-003 - Drug Profile 135
PD-2015 - Drug Profile 136
PD-2016 - Drug Profile 137
PD-2024 - Drug Profile 138
PD-2244 - Drug Profile 139
PD-61W3 - Drug Profile 140
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 141
PST-900 - Drug Profile 142
RVT-101 - Drug Profile 143
salicylamine - Drug Profile 144
SIN-1502 - Drug Profile 145
Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 146
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 147
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 148
Small Molecules for Frontotemporal Dementia - Drug Profile 149
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 150
Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 151
Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile 152
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile 153
SND-14 - Drug Profile 154
SYN-120 - Drug Profile 155
Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 156
TAK-070 - Drug Profile 157
TauC-3 - Drug Profile 158
TPI-287 - Drug Profile 159
TRx-0237 - Drug Profile 162
TTT-3002 - Drug Profile 164
WIB-1001C - Drug Profile 165
zonisamide - Drug Profile 166
Dementia - Recent Pipeline Updates 167
Dementia - Dormant Projects 194
Dementia - Discontinued Products 199
Dementia - Product Development Milestones 200
Featured News & Press Releases 200
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 212
Disclaimer 213

List of Tables
Number of Products under Development for Dementia, H1 2016 16
Number of Products under Development for Dementia - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Development, H1 2016 24
Comparative Analysis by Unknown Stage Development, H1 2016 25
Products under Development by Companies, H1 2016 26
Products under Development by Companies, H1 2016 (Contd..1) 27
Products under Development by Companies, H1 2016 (Contd..2) 28
Products under Development by Companies, H1 2016 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2016 30
Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 31
Dementia - Pipeline by AgeneBio Inc., H1 2016 32
Dementia - Pipeline by Alector LLC, H1 2016 33
Dementia - Pipeline by AlzProtect SAS, H1 2016 34
Dementia - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 35
Dementia - Pipeline by Axon Neuroscience SE, H1 2016 36
Dementia - Pipeline by Axovant Sciences Ltd., H1 2016 37
Dementia - Pipeline by BioArctic Neuroscience AB, H1 2016 38
Dementia - Pipeline by Biogen, Inc., H1 2016 39
Dementia - Pipeline by Biotie Therapies Corp., H1 2016 40
Dementia - Pipeline by Boehringer Ingelheim GmbH, H1 2016 41
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H1 2016 42
Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 43
Dementia - Pipeline by Eisai Co., Ltd., H1 2016 44
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H1 2016 45
Dementia - Pipeline by H. Lundbeck A/S, H1 2016 46
Dementia - Pipeline by Heptares Therapeutics Limited, H1 2016 47
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 48
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2016 49
Dementia - Pipeline by Immungenetics AG, H1 2016 50
Dementia - Pipeline by ImStar Therapeutics Inc., H1 2016 51
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 52
Dementia - Pipeline by Intellect Neurosciences, Inc., H1 2016 53
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 54
Dementia - Pipeline by MediPost Co., Ltd., H1 2016 55
Dementia - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016 56
Dementia - Pipeline by Neurimmune Holding AG, H1 2016 57
Dementia - Pipeline by Neurodyn Inc., H1 2016 58
Dementia - Pipeline by Oryzon Genomics S.A., H1 2016 59
Dementia - Pipeline by Ovid Therapeutics Inc., H1 2016 60
Dementia - Pipeline by P2D Bioscience, H1 2016 61
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H1 2016 62
Dementia - Pipeline by Pivot Pharmaceuticals Inc, H1 2016 63
Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016 64
Dementia - Pipeline by Stelic Institute & Co., Inc., H1 2016 65
Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 66
Dementia - Pipeline by Sylentis S.A.U., H1 2016 67
Dementia - Pipeline by TauRx Therapeutics Ltd., H1 2016 68
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016 69
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Stage and Target, H1 2016 73
Number of Products by Stage and Mechanism of Action, H1 2016 76
Number of Products by Stage and Route of Administration, H1 2016 79
Number of Products by Stage and Molecule Type, H1 2016 81
Dementia Therapeutics - Recent Pipeline Updates, H1 2016 173
Dementia - Dormant Projects, H1 2016 200
Dementia - Dormant Projects (Contd..1), H1 2016 201
Dementia - Dormant Projects (Contd..2), H1 2016 202
Dementia - Dormant Projects (Contd..3), H1 2016 203
Dementia - Dormant Projects (Contd..4), H1 2016 204
Dementia - Discontinued Products, H1 2016 205